Effects of Incretin-Based Pharmacotherapies on Lean Body Mass in Adults With Overweight, Obesity, or Type 2 Diabetes: A Systematic Review With Prespecified Network Meta-Analysis Feasibility Assessment.
Incretin-based therapies are associated with measurable reductions in lean body mass, but the clinical significance of these findings remains uncertain due to study limitations.
Where it sits
this study against the rest of the mazdutide (ibi362) corpusSummary and findings
This study assessed the effects of incretin-based pharmacotherapies on lean body mass in adults with overweight, obesity, or type 2 diabetes. The primary outcome was the relative percentage change in total lean body mass measured by DXA at 48 to <80 weeks. Key secondary outcomes included absolute changes in lean body mass in kilograms.
Abstract
Incretin-based pharmacotherapies produce substantial weight loss, but their comparative effects on lean tissue remain incompletely characterized. We systematically reviewed randomized controlled trials in adults with overweight, obesity, and/or type 2 diabetes. The prospectively registered primary outcome was the between-group difference in relative percentage change from baseline in total lean body mass measured by dual-energy X-ray absorptiometry (DXA) at 48 to <80 weeks; absolute DXA change in kilograms was the key secondary outcome. The auditable record-level dataset comprised 6,526 imported records from PubMed and ClinicalTrials.gov; after the removal of 250 within-PubMed duplicates, 6,276 records were screened, and 52 trial families met review-level eligibility. Three direct contrasts had defensible precision for the registered primary outcome: pooled tirzepatide versus placebo, -8.3 percentage points (95% confidence interval {CI}: -10.6 to -6.1); semaglutide 1.0 mg versus placebo, -3.81 (-6.57 to -1.06); and semaglutide 2.4 mg versus placebo, -6.06 (-8.79 to -3.33). Because the two BELIEVE semaglutide contrasts shared a placebo group and their joint covariance was unavailable, they were not treated as independent edges in a single dose-specific network meta-analysis (NMA). Separate placebo-anchored sensitivity comparisons of pooled tirzepatide versus semaglutide were -4.49 percentage points (95% CI: -8.05 to -0.93) for semaglutide 1.0 mg and -2.24 (-5.78 to 1.30) for semaglutide 2.4 mg; both were graded very low confidence. For the key secondary absolute DXA outcome, mean differences versus placebo were -3.43 kg (95% CI: -4.74 to -2.13) for semaglutide 2.4 mg, -4.40 kg (-5.60 to -3.20) for pooled tirzepatide, and -5.90 kg (-7.28 to -4.52) for mazdutide 9 mg. DXA-derived lean mass is not synonymous with skeletal-muscle mass or function, and these reductions should not by themselves be interpreted as evidence of sarcopenia or clinically harmful muscle loss. Randomized evidence therefore supports measurable lean-mass loss during incretin-associated weight reduction, but sparse network geometry, heterogeneous estimands, selected body-composition substudies, and incomplete reporting preclude a reliable comparative treatment ranking.
Background
This paper addresses the comparative effects of incretin-based pharmacotherapies on lean body mass, a critical aspect often overshadowed by weight loss outcomes. Prior studies have established that these therapies can lead to significant weight loss, but their impact on lean tissue remains less understood. Understanding these effects is essential for evaluating the overall health implications of such treatments in populations with overweight, obesity, or type 2 diabetes.
Methods
The study systematically reviewed randomized controlled trials involving adults with overweight, obesity, or type 2 diabetes. The primary outcome was the between-group difference in relative percentage change from baseline in total lean body mass, measured by dual-energy X-ray absorptiometry (DXA) at 48 to <80 weeks. A total of 52 trial families met the eligibility criteria after screening 6,276 records.
Results
The primary endpoint revealed a -8.3 percentage point difference in lean body mass for pooled tirzepatide compared to placebo (95% CI: -10.6 to -6.1). For the key secondary absolute DXA outcome, mazdutide 9 mg showed a mean difference of -5.90 kg versus placebo (95% CI: -7.28 to -4.52). Other notable findings included -3.81 percentage points for semaglutide 1.0 mg and -6.06 percentage points for semaglutide 2.4 mg compared to placebo.
Interpretation
These findings suggest that incretin-based therapies are associated with measurable reductions in lean body mass, which is statistically significant but may not be clinically meaningful. The effect sizes, particularly for mazdutide, indicate a loss of lean mass that warrants caution in interpretation, especially given the limitations of the study. Confounding factors such as small sample sizes and incomplete reporting may impact the reliability of these conclusions.
Key findings
- -8.3 percentage points relative change in lean body mass for pooled tirzepatide versus placebo (95% CI: -10.6 to -6.1)
- -3.81 percentage points for semaglutide 1.0 mg versus placebo (95% CI: -6.57 to -1.06)
- -6.06 percentage points for semaglutide 2.4 mg versus placebo (95% CI: -8.79 to -3.33)
- -4.40 kg absolute change for pooled tirzepatide versus placebo (95% CI: -5.60 to -3.20)
- -5.90 kg absolute change for mazdutide 9 mg versus placebo (95% CI: -7.28 to -4.52)
Limitations
- sparse network geometry
- heterogeneous estimands
- incomplete reporting
- small sample sizes in some trials
- short follow-up period